{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:45Z","timestamp":1790263185235,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"suppl_9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI14\/00391"],"award-info":[{"award-number":["FI14\/00391"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1093\/infdis\/jix430","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T19:10:05Z","timestamp":1502997005000},"page":"S847-S850","source":"Crossref","is-referenced-by-count":61,"title":["The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure"],"prefix":"10.1093","volume":"216","author":[{"given":"Natalia","family":"Stella-Ascariz","sequence":"first","affiliation":[{"name":"Microbiology Service, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Arribas","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"HIV Unit and irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona and Universitat de Vic-UCC, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Z","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"key\n\t\t\t\t20180328161421_CIT0001","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/JCM.41.4.1586-1593.2003","article-title":"Accuracy of the TRUGENE HIV-1 genotyping kit","volume":"41","author":"Grant","year":"2003","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328161421_CIT0002","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/JCM.37.7.2291-2296.1999","article-title":"Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Schuurman","year":"1999","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328161421_CIT0003","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jviromet.2007.06.012","article-title":"Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations","volume":"146","author":"Paredes","year":"2007","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20180328161421_CIT0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jviromet.2011.11.030","article-title":"Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay","volume":"192","author":"Ellis","year":"2013","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20180328161421_CIT0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","article-title":"Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome","volume":"50","author":"Jakobsen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0006","doi-asserted-by":"crossref","first-page":"e90485","DOI":"10.1371\/journal.pone.0090485","article-title":"Comparison of Illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0007","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/AAC.02710-13","article-title":"Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism","volume":"58","author":"Gibson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0008","doi-asserted-by":"crossref","first-page":"e36494","DOI":"10.1371\/journal.pone.0036494","article-title":"Low-cost ultra-wide genotyping using Roche\/454 pyrosequencing for surveillance of HIV drug resistance","volume":"7","author":"Dudley","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0009","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0010","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328161421_CIT0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e32834e9d7d","article-title":"Relationship between minority NNRTI resistance mutations, adherence, and the risk of virologic failure","volume":"26","author":"Li","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0012","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0013","first-page":"672","article-title":"Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients","volume":"201","author":"Halvas","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0014","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/QAD.0000000000000748","article-title":"Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease","volume":"29","author":"Casadell\u00e0","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0015","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/QAD.0000000000001033","article-title":"Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing","volume":"30","author":"Casadell\u00e0","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0016","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/jac\/dkv048","article-title":"Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response","volume":"70","author":"Charpentier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0017","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00038-16","article-title":"Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure","volume":"60","author":"Kyeyune","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0018","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000000267","article-title":"Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure","volume":"28","author":"Mohamed","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135941","article-title":"Longitudinal detection and persistence of minority drug-resistant populations and their effect on salvage therapy","volume":"10","author":"Nishizawa","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0022","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/596486","article-title":"Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"48","author":"Coovadia","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0023","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1105688108","article-title":"Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine","volume":"108","author":"Boltz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180328161421_CIT0024","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa062876","article-title":"Response to antiretroviral therapy after a single, peripartum dose of nevirapine","volume":"356","author":"Lockman","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328161421_CIT0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/infdis\/jit635","article-title":"Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP","volume":"209","author":"Boltz","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0026","unstructured":"Derache A , IwujiCC, DanaviahS Prevalence and impact of pretreatment drug resistance in the ANRS 12249 TASP TRIAL [abstract 43]. In: 24th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2017."},{"key":"key\n\t\t\t\t20180328161421_CIT0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/COH.0b013e328322f973","article-title":"Current tests to evaluate HIV-1 coreceptor tropism","volume":"4","author":"Rose","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0028","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/QAD.0b013e32832b4399","article-title":"Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing","volume":"23","author":"Archer","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0029","doi-asserted-by":"crossref","first-page":"e1001022","DOI":"10.1371\/journal.pcbi.1001022","article-title":"The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time\u2014an ultra-deep approach","volume":"6","author":"Archer","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"key\n\t\t\t\t20180328161421_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0005683","article-title":"Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo","volume":"4","author":"Tsibris","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0031","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328161421_CIT0032","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"Swenson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0033","doi-asserted-by":"crossref","first-page":"e46334","DOI":"10.1371\/journal.pone.0046334","article-title":"A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients","volume":"7","author":"Kagan","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0034","first-page":"850","article-title":"Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing","volume":"72","author":"Stefic","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2010.09.016","article-title":"Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure","volume":"88","author":"Codo\u00f1er","year":"2010","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180328161421_CIT0036","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e3283367796","article-title":"High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0037","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.01492-10","article-title":"Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment","volume":"55","author":"Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328161421_CIT0038","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/QAD.0b013e32834b34de","article-title":"Switching between raltegravir resistance pathways analyzed by deep sequencing","volume":"25","author":"Mukherjee","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328161421_CIT0039","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"Armenia","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1293.2012.01039.x","article-title":"Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens","volume":"14","author":"Nguyen","year":"2013","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328161421_CIT0041","doi-asserted-by":"crossref","first-page":"e104512","DOI":"10.1371\/journal.pone.0104512","article-title":"Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy","volume":"9","author":"Gibson","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0042","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcv.2015.11.009","article-title":"Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing","volume":"73","author":"Fonager","year":"2015","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180328161421_CIT0043","doi-asserted-by":"crossref","first-page":"e30118","DOI":"10.1371\/journal.pone.0030118","article-title":"Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing","volume":"7","author":"Lataillade","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0010952","article-title":"Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study","volume":"5","author":"Lataillade","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328161421_CIT0045","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1128\/JVI.06541-11","article-title":"Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen","volume":"86","author":"Fisher","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328161421_CIT0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 Antiretroviral resistance scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180328161421_CIT0047","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20180328161421_CIT0048","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe","volume":"62","author":"Hofstra","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0049","first-page":"1","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328161421_CIT0050","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1086\/651136","article-title":"Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy","volume":"201","author":"Metzner","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328161421_CIT0051","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dku278","article-title":"Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries","volume":"69","author":"Ekici","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_9\/S847\/24264822\/jix430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T10:14:00Z","timestamp":1659348840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_9\/S847\/4683196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":51,"journal-issue":{"issue":"suppl_9","published-online":{"date-parts":[[2017,12,1]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix430","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,15]]},"published":{"date-parts":[[2017,11,15]]}}}